- Home
- DOYU vs NKTX Comparison
DOYU vs NKTX Comparison
Compare DOYU & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOYU | NKTX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.0M | 154.8M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DOYU | NKTX |
|---|---|---|
| Price | $4.68 | $2.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $7.00 | ★ $12.00 |
| AVG Volume (30 Days) | 27.7K | ★ 604.5K |
| Earning Date | 03-25-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.28 | $1.42 |
| 52 Week High | $9.34 | $2.81 |
Technical Indicators
Market Signals| Indicator | DOYU | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.19 | 37.26 |
| Support Level | $4.28 | $1.95 |
| Resistance Level | $7.11 | $2.16 |
| Average True Range (ATR) | 0.21 | 0.12 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 15.91 | 9.18 |
Price Performance
Historical ComparisonAbout DOYU DouYu International Holdings Limited ADS
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.